sante.lefigaro.fr
🌐 % Global Worthiness
French Health Authority Rejects Early Access to Biogen's ALS Drug
The French health authority denied early access to Biogen's ALS drug Qalsody due to insufficient clinical trial data, sparking controversy and raising questions about its potential effectiveness.
French Health Authority Rejects Early Access to Biogen's ALS Drug
The French health authority denied early access to Biogen's ALS drug Qalsody due to insufficient clinical trial data, sparking controversy and raising questions about its potential effectiveness.
Progress
0% Bias Score